A Phase 2 open-label, multicenter, single arm trial of ImmunoPulse IL-12 in combination with an anti-PD-1 therapy in subjects with inoperable locally advanced or metastatic triple negative breast cancer.
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Tavokinogene telsaplasmid (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jan 2018 New trial record
- 03 Jan 2018 According to an OncoSec Medical media release, this trial will initiate in 2018.